ALN-4324
Phase 2Small molecule
Alnylam PharmaceuticalsALN-4324 is one of 38 small molecule programs targeting Type 2 Diabetes Mellitus. It is currently in Phase 2.
1
Indications
2
Total Trials
2
Active Trials
37
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
676 competitors in Type 2 Diabetes Mellitus
#DrugCompanyPhaseTrials
1Tanzeum
GSKPreclinical
Insulin 320
Novo NordiskPreclinical
Adenocard
AstellasPreclinical
NOVOLIN R
Novo NordiskPreclinical
Dostinex
PfizerPreclinical
Cipro
BayerPreclinical
Myrbetriq
AstellasPreclinical
Golytely
BayerPreclinical
Lantus
SanofiPreclinical
Lixisenatide
SanofiPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ALN-4324. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company